Jiang Zhong Pharmaceutical (SHA:600750) recorded an attributable profit of 784.9 million yuan in 2024, up 9.2% from 718.7 million yuan in 2023.
The Chinese drugmaker's basic earnings per share stood at 1.25 yuan in 2024, up from 1.14 yuan in 2023.
Total operating revenue fell 2.6% to 4.44 billion yuan from 4.55 billion yuan a year prior, according to a Jan. 24 bourse filing by parent China Resources Pharmaceutical Group (HKG:3320).
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.